Extending the life of β-lactam antibiotics: New β-lactamase inhibitors

Drug Discovery Today: Therapeutic Strategies

Volumn 3, Issue 2, 2006, Pages 183-188

  Coleman, Ken ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4 AMINO 1,1 DIMETHYLBUTYL) 6 (1 HYDROXYETHYL)OXAPENEM 3 CARBOXYLIC ACID; 6 (1 METHYL 1,2,3 TRIAZOL 4 YLMETHYLENE)PENEM 3 CARBOXYLIC ACID; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; BETA LACTAMASE INHIBITOR; CARBAPENEM; CLAVULANIC ACID; NXL 104; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; SB 206999; SULBACTAM; SULPERAZON; SULPERAZONE; SULTAMICILLIN; SYN 2190; TAZOBACTAM; TIMENTIN; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; DRUG MARKETING; DRUG STRUCTURE; ENZYME INHIBITION; HUMAN; MOLECULAR MECHANICS; REVIEW; STRUCTURE ANALYSIS;

EID: 33746837246     PISSN: 17406773     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddstr.2006.06.010     Document Type: Review

References (35)

1. Helfand M.S., and Bonomo R.A. β-Lactamases: a survey of protein diversity. Curr. Drug Targets Infect. Dis. 3 (2003) 9-23
2. Paterson D.L., and Bonomo R.A. Extended-spectrum β-lactamases: a clinical update. Clin. Mic. Rev. 18 (2005) 657-686
3. Jacoby G.A., and Munoz-Price L.S. The new β-lactamases. N. Engl. Med. J. 352 (2005) 380-391
4. Jacoby G.A., and Bush K. β-Lactamase nomenclature. J. Clin. Microbiol. 43 (2005) 6220
5. Ambler R.P. The structure of β-lactamases. Philos. Trans. R. Soc. Lond. (Biol.) 289 (1980) 321-331
6. Hall B.G., and Barlow M. Revised ambler classification of β-lactamases. J. Antimicrob. Chemother 55 (2005) 1050-1051
7. Frère J.M., et al. Is it necessary to change the classification of β-lactamases?. J. Antimicrob. Chemother. 55 (2005) 1051-1053
8. Chaibi E.B., et al. Inhibitor-resistant TEM β-lactamases: phenotypic, genetic and biochemical characteristics. J. Antimicrob. Chemother. 43 (1999) 447-458
9. Cricco J.A., and Vila A.J. Class B β-lactamases: the importance of being metallic. Curr. Pharm. Des. 5 (1999) 915-927
10. Jones R.N. Important and emerging β-lactamase-mediated resistances in hospital-based pathogens: the AmpC enzymes. Diagn. Microbiol. Infect. Dis. 31 (1998) 461-466
11. Livermore D.M. Clinical significance of β-lactamase induction and stable depression on Gram-negative rods. Eur. J. Clin. Mic. 6 (1987) 439-445
12. Naas T., and Nordmann P. OXA-type β-lactamases. Curr. Pharm. Des. 5 (1999) 865-879
13. Brown S., and Amyes S. OXA β-lactamases in Acinetobacter: the story so far. J. Antimicrob. Chemother. 57 (2006) 1-3
14. Navarro A.S. New formulations of amoxicillin/clavulanic acid; a pharmacokinetic and pharmacodynamic review. Clin. Pharmacokinet. 44 (2005) 1097-1115
15. Levin A.S. Multiresistant Acinetobacter infections: a role for sulbactam combinations in overcoming an emerging worldwide problem. Clin. Mic. Infect. 8 (2002) 144-153
16. Mathai D., et al. Antibacterial activity of 41 antimicrobials tested against over 2773 bacterial isolates from hospitalized patients with pneumonia: 1: results from the SENTRY antimicrobial surveillance program (North America, 1998). Diag. Microbiol. Infect. Dis. 39 (2001) 105-116
17. Payne D.J., et al. β-lactamase epidemiology and the utility of established and novel β-lactamase inhibitors. Exp. Opin. Invest. Drugs 9 (2000) 247-261
18. st century: current agents and new developments. Curr. Opin. Pharmacol. 1 (2001) 451-458
19. Lee N., et al. Clinical role of β-lactam/β-lactamase inhibitor combinations. Drugs 63 (2003) 1511-1524
20. Buynak J.D. The discovery and development of modified penicillin- and cephalosporin-derived β-lactamase inhibitors. Curr. Med. Chem. 11 (2004) 1951-1964
21. Bennett I., et al. 6-(Substituted methylene)penems, potent broad-spectrum inhibitors of bacterial β-lactamase. IV. Kidney stability, serum binding and additional biological evaluation of racemic derivatives. J. Antibiot. 44 (1991) 338-343
22. Bennett I., et al. 6-(Substituted methylene)penems, potent broad-spectrum inhibitors of bacterial β-lactamase V. Chiral 1,2,3-triazolyl derivatives. J. Antibiot. 44 (1991) 967-978
23. Coleman K., et al. In vitro evaluation of BRL 42715, a novel β-lactamase inhibitor. Antimicrob. Agents Chemother. 33 (1989) 1580-1587
24. Coleman K., et al. Pharmakokinetic studies and renal dehydropeptidase stability of the new β-lactamase inhibitor BRL 42715 in animals. Antimicrob. Agents Chemother. 35 (1991) 1748-1752
25. Prince, W.T. et al. (1990) Effect of BRL 42715 on the pharmacokinetics of piperacillin following intravenous administration. Program Abstract. 30th Interscience Conference on Antimicrobial Agents and Chemotherapy (Abstract 823)
26. Coleman K. An update on β-lactamases and β-lactamase inhibitors. Exp. Opin. Invest. Drugs 4 (1995) 693-704
27. Phillips O.A., et al. SYN-1012: A new β-lactamase inhibitor of penem skeleton. J. Antibiot. 50 (1997) 350-356
28. Venkatesan A., et al. Novel imidazole substituted 6-methylidene-penems as broad-spectrum β-lactamase inhibitors. Bioorg. Med. Chem. 12 (2004) 5807-5817
29. Weiss W.J., et al. In vitro and in vivo activities of novel 6-methylidene penems as β-lactamase inhibitors. Antimicrob. Agents Chemother. 48 (2004) 4589-4596
30. Jamieson C.E., et al. In vitro and in vivo activities of AM-112, a novel oxapenem. Antimicrob. Agents Chemother. 47 (2003) 1652-1657
31. Jamieson C.E., et al. In vitro activities of novel oxapenems, alone and in combination with ceftazidime, against Gram-positive and Gram-negative organisms. Antimicrob. Agents Chemother. 47 (2003) 2615-2618
32. Nishida K., et al. In vitro and in vivo activities of Syn2190, a novel β-lactamase inhibitor. Antimicrob. Agents Chemother. 43 (1999) 1895-1900
33. Bonnefoy A., et al. In vitro activity of AVE1330A, an innovative broad-spectrum non-β-lactam β-lactamase inhibitor. J. Antimicrob. Chemother. 54 (2004) 410-417
34. Miossec, C. et al. (2005) Safety and toxicokinetics of NXL104, a broad spectrum beta-lactamase inhibitor, in the rat. Program Abstract. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC (Abstract F-1461)
35. Buynak J.D., et al. Penicillin-derived inhibitors that simultaneously target both metallo- and serine-β-lactamases. Bioorg. Med. Chem. Lett. 14 (2004) 1299-1304